Replimune Group, Inc.
Replimune Group, Inc. (REPL) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · REPL · as of Mar 31, 2025
Ownership Breakdown
170
Institutional Holders
▲ 10 vs Q4
$799.31M
Total Inst. Value
▼ $143.91M vs Q4
82.57M
Shares Outstanding
freeFloat 92.33%
81.98M
13F Shares Held
▲ 4.09M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
REPL largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BAKER BROS. ADVISORS LP biological products, (no diagnostic substances) | 11.05M | 13.23% | 13.23% | $107.69B | May 15, 2025 | — held |
PRICE T ROWE ASSOCIATES INC /MD/ biological products, (no diagnostic substances) | 10.85M | 13.00% | 13.00% | $105.83B | May 14, 2025 | ▼ 109.1K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 6.06M | 7.26% | 7.26% | $59.10B | May 2, 2025 | ▲ 495.5K |
REDMILE GROUP, LLC biological products, (no diagnostic substances) | 4.90M | 5.87% | 5.87% | $47.76B | May 15, 2025 | ▼ 7.0K |
FCPM III SERVICES B.V. biological products, (no diagnostic substances) | 3.91M | 4.85% | 4.85% | $38.12B | May 15, 2025 | ▼ 61.0K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 3.83M | 4.59% | 4.59% | $37.37B | May 9, 2025 | ▲ 237.2K |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 2.90M | 3.47% | 3.47% | $28.27B | May 15, 2025 | ▲ 200.0K |
MARSHALL WACE, LLP biological products, (no diagnostic substances) | 2.49M | 2.98% | 2.98% | $24.25B | May 15, 2025 | ▲ 1.59M |
SOFINNOVA INVESTMENTS, INC. biological products, (no diagnostic substances) | 2.48M | 2.97% | 2.97% | $24.18B | May 15, 2025 | ▼ 669.6K |
STATE STREET CORP biological products, (no diagnostic substances) | 2.40M | 2.87% | 2.87% | $23.38B | May 15, 2025 | ▲ 194.0K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
27
Increased
+5.46M shares5
New Positions
first time holders13
Decreased
−1.70M shares0
Sold Out
fully exitedNet shares change (top 50)
+3.76M
+5.46M / −1.70M
Net new holders
+19
5 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
REPL insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
19
Buy transactions
8
Sell transactions
2.38
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Sarchi Christopher Chief Commercial Officer | Jun 1, 2026 | Sale | 12,000 | $9.24 | $110.9K | 181.0K | Form 4 ↗ |
Xynos Konstantinos Chief Medical Officer | May 18, 2026 | Sale | 14,023 | $5.08 | $71.2K | 235.7K | Form 4 ↗ |
Schwendenman Andrew Chief Accounting Officer | May 18, 2026 | Sale | 7,894 | $5.08 | $40.1K | 107.1K | Form 4 ↗ |
Sarchi Christopher Chief Commercial Officer | May 18, 2026 | Sale | 8,626 | $5.08 | $43.8K | 193.0K | Form 4 ↗ |
Astley-Sparke Philip director | May 18, 2026 | Sale | 17,657 | $5.08 | $89.7K | 1.41M | Form 4 ↗ |
Patel Sushil Chief Executive Officer | May 18, 2026 | Sale | 37,324 | $5.08 | $189.6K | 747.5K | Form 4 ↗ |
Hill Emily Luisa Chief Financial Officer | May 18, 2026 | Sale | 7,812 | $5.08 | $39.7K | 236.6K | Form 4 ↗ |
BAKER BROS. ADVISORS LP
| Apr 1, 2026 | Award | 44,500 | $7.61 | $338.6K | 44.5K | Form 4 ↗ |
Sarchi Christopher Chief Commercial Officer | Apr 1, 2026 | Award | 50,000 | — | — | 201.6K | Form 4 ↗ |
Sarchi Christopher Chief Commercial Officer | Apr 1, 2026 | Award | 75,000 | $7.61 | $570.8K | 75.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Replimune Group, Inc. (REPL) is primarily owned by institutional investors, who hold approximately 99.3% of total shares outstanding. Company insiders own approximately 7.67%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Replimune Group, Inc. is BAKER BROS. ADVISORS LP, holding approximately 11.05 million shares — equal to 13.23% of outstanding shares — as of March 31, 2025.
A total of 170 institutional investors currently hold REPL stock, with a combined institutional value of approximately $799,309,539 as of the most recent 13F filing period.
Frequently asked questions
REPL ownershipReplimune Group, Inc. (REPL) is primarily owned by institutional investors, who hold approximately 99.3% of shares. The largest shareholder is BAKER BROS. ADVISORS LP with a 13.23% stake. Company insiders hold 7.67%. Data sourced from SEC Form 13F as of March 31, 2025.